09 Apr Pseudoephedrine-containing medicines – Risks of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS) – Reckit
Posted at 14:29h
in
Reckitt Benckiser Pharmaceuticals (Pty) Ltd in collaboration with the South African Health Products Regulatory Authority (SAHPRA), wish to draw your attention to the risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome associated with the use of pseudoephedrine-containing medicines.
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
09/04/2025
File Type:
pdf
Category:
Communication To Health Care Professionals